Showing results (261-270 of 286) with videos related to
Sort By:
Pageof 29
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.Neuro-Oncology|April 21, 2021
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.The Lancet. Oncology|November 14, 2021
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 studyHussein A Tawbi, Peter A Forsyth, F Stephen Hodi, et al.European Journal of Cancer (Oxford, England : 1990)|January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patientsJulie R Brahmer, Georgina V Long, Omid Hamid, et al.Journal for Immunotherapy of Cancer|October 18, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, et al.The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.Iscience|September 17, 2024
Low booster uptake in cancer patients despite health benefitsJane C Figueiredo, Julia Levy, So Yung Choi, et al.Medrxiv : the Preprint Server for Health Sciences|November 14, 2023
Low booster uptake in cancer patients despite health benefitsJane C Figueiredo, Julia Levy, So Yung Choi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2021
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic MelanomaAmod A Sarnaik, Omid Hamid, Nikhil I Khushalani, et al.JAMA|April 20, 2016
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced MelanomaAntoni Ribas, Omid Hamid, Adil Daud, et al.Pageof 29